ABSTRACT
BACKGROUND: Tubal patency testing constitutes an essential part of infertility work-up. Hysterosalpingo-foam-sonography (HyFoSy) is currently one of the best tests for assessing tubal patency. The objective of our study was to evaluate the post-procedure rate of spontaneous pregnancy among infertile women submitted for an HyFoSy exam with ExEm® foam and the factors associated with this. METHODS: Multicenter, prospective, observational study performed at six Spanish centers for gynecologic sonography and human reproduction. From December 2015 to June 2021, 799 infertile women underwent HyFoSy registration consecutively. The patients' information was collected from their medical records. Multivariable regression analyses were performed, controlling for age, etiology, and time of sterility. The main outcome was to measure post-procedure spontaneous pregnancy rates and the factors associated with the achievement of pregnancy. RESULTS: 201 (26.5%) women got spontaneous conception (SC group), whereas 557 (73.5%) women did not get pregnant (non-spontaneous conception group, NSC). The median time for reaching SC after HyFoSy was 4 months (CI 95% 3.1-4.9), 18.9% of them occurring the same month of the procedure. Couples with less than 18 months of infertility were 93% more likely to get pregnant after HyFoSy (OR 1.93, 95% CI 1.34-2.81; p < 0.001); SC were two times more frequent in women under 35 years with unexplained infertility (OR 2.22, 95% CI 1.07-4.65; P0.033). CONCLUSION: After HyFoSy, one in four patients got pregnant within the next twelve months. Couples with shorter infertility time, unexplained infertility, and women under 35 years are more likely to achieve SC after HyFoSy.
ABSTRACT
Objective: This is a prospective observational study whose goal was to compare the effectiveness of carbetocin and oxytocin for prevention of postpartum hemorrhage (PPH) when they are administered in twin pregnancies undergoing a cesarean section.Design: We enrolled 166 twin pregnancies at term undergoing elective or emergency cesarean section. We compared the effect of a single 100 µg dose of carbetocin with the use of oxytocin as a protocol (20 IU in Ringer lactate 500 ml in 10-15 min). The main variables studied were intraoperative bleeding, surgical time, hemoglobin fall, hematocrit drop, additional uterotonic use (Methylergometrine and/or misoprostol), need for blood transfusion, and/or IV iron therapy.Results: In the oxytocin group there was a greater fall in the hemoglobin level (1.7 versus 1.2, p = .02). Along the same line, the control group presented a significantly greater need for blood transfusion (9.3 versus 1.3%, =0.03), as well as treatment for anemia as a composite variable (intravenous (IV) iron therapy and/or blood transfusion) 16.3 versus 3.85% for each group [OR 0.2 (0.05-0.72)]. In addition, the use of carbetocin was associated with a reduction in the need to administer additional treatments (uterotonic and/or treatment for anemia) during the postpartum period compared with the use of oxytocin O.R 0.32 (0.12-0.88).Conclusions: In our population of twin pregnancies delivered by cesarean section, carbetocin appears more effective than oxytocin in preventing PPH.
